What Vetter Pharma’s Saarland project reveals about long-cycle CDMO investment strategies
Vetter Pharma commits €480M to build a new commercial injectable manufacturing site in Saarland, Germany; explore industry impact and CDMO capacity shifts.
What Quince’s failed NEAT trial reveals about rare pediatric trial design risks
Quince Therapeutics ends clinical development of eDSP for A-T after Phase 3 failure. Find out what this means for its platform and future strategy.
What KORU Medical’s RYSTIGGO delivery clearance means for subcutaneous infusion models
KORU Medical’s FreedomEDGE gets FDA clearance for RYSTIGGO delivery in clinics. Find out how this expands access to gMG therapy and reshapes infusion workflows.
Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?
Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.
Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?
Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.
What Hera BioLabs’ absorption into Demeetra reveals about IP bottlenecks in gene editing R&D
Demeetra’s acquisition of Hera BioLabs consolidates Super piggyBac IP. Find out how this could reshape gene therapy tools and licensing frameworks.
Sinorda bets on bispecifics with WuXi Biologics for IBD and autoimmune expansion
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006, […]
Johnson & Johnson expands DARZALEX FASPRO label with new D-VRd approval in newly diagnosed myeloma
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.